Self-assembling molecules that can be programmed like robots to carry out specific tasks without requiring power. Re-engineered living cells and biological circuits as programmable devices for medicine, manufacturing and sustainability. Material-based systems capable of modulating immune cells ex vivo and in the human body to treat or diagnose disease. Candidate diagnostics will be driven by clinicians’ unmet needs, advanced in the Wyss Institute’s biomarker discovery and technology development labs, and validated in BWH’s CLIA lab, providing crucial clinical data to move them from the bench to the bedside faster.
Therapeutic discovery and diagnostics development enabled by microsystems engineering, molecular engineering, computational design, and organ-on-a-chip in vitro human experimentation technology.Īn initiative enabling the creation of new diagnostic technologies that solve high-value clinical problems through deep collaboration between the Wyss Institute and Brigham and Women’s Hospital.
